PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 85.81

Change

-0.71 (-0.82)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-03 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.38 (-0.90%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

-0.71 (-0.98%)

USD 2.97B
FXH First Trust Health Care AlphaD..

-1.54 (-1.40%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-1.47 (-1.67%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.35 (-1.43%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.57 (-1.53%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-1.47 (-1.55%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.56 (-1.91%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.89 (-1.41%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.36 (-1.32%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.76% 95% A 65% D
Dividend Return 0.76% 56% F 12% F
Total Return 13.52% 95% A 60% D-
Trailing 12 Months  
Capital Gain 19.93% 67% D+ 53% F
Dividend Return 1.08% 56% F 12% F
Total Return 21.01% 62% D 47% F
Trailing 5 Years  
Capital Gain 52.42% 62% D 71% C-
Dividend Return 4.24% 56% F 12% F
Total Return 56.66% 57% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.57% N/A N/A 60% D-
Dividend Return 7.16% N/A N/A 54% F
Total Return 0.59% N/A N/A 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.91% N/A N/A 70% C-
Risk Adjusted Return 55.51% N/A N/A 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike